Skip to main content

Turkey prepares to distribute Chinese vaccine

With the Turkish government expected to begin mass distribution of the Chinese-made COVID-19 vaccine Sinovac this week, health experts are questioning its effectiveness and the state’s rollout strategy.

A health worker administers a dose of Sinovac Biotech potential vaccine against the COVID-19 to Doctor Cem Gun (L) during the 3rd phase trials at the Acibadem Hospital in Istanbul, on October 9, 2020.Y (Photo by Yasin AKGUL / AFP) (Photo by YASIN AKGUL/AFP via Getty Images)
A health worker administers a dose of the Sinovac Biotech vaccine against COVID-19 to Dr. Cem Gun (L) during the 3rd phase trials at the Acibadem Hospital in Istanbul, on Oct. 9, 2020. — YASIN AKGUL/AFP via Getty Images

ISTANBUL ­— The Turkish government is expected to begin mass distribution of a COVID-19 vaccine produced by China’s Sinovac Biotech this week as questions remain over its efficacy rate.

The rollout is expected to begin Thursday or Friday if testing by the Turkish Medicines and Medical Devices Agency delivers positive results today. An interim analysis last month by Turkish researchers found the Sinovac vaccine to be 91.25% effective while preliminary tests in Indonesia showed a 65% efficacy rate, leading officials there to grant the vaccine emergency approval Monday.

Previously, final-stage trials in Brazil found the vaccine to be 50.38% effective, though Sinovac CEO Yin Weidong told reporters Wednesday the disparity was caused by the participation of high-risk medical workers in the Brazilian study.

The developments come as Turkey is expected to receive 10 million doses of the Sinovac vaccine in the next two weeks, adding to three million doses received late last month. Turkey has contracted to purchase a total of 50 million Sinovac doses. State officials have also agreed to procure 4.5 million doses of the Pfizer-BioNTech vaccine, which has been found to have a 95% efficacy rate.

SUBSCRIBER EXCLUSIVE

Continue reading this exclusive analysis

Original reporting and analysis unavailable elsewhere. Subscribe to AL-MONITOR to read this story and access everything we publish